Seminars in Nuclear Medicine
Volume 31, Issue 2 , Pages 158-164 , April 2001

Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology

    MD, PhD
  • Brian J. Czerniecki

      Affiliations

    • Department of Surgery, University of Pennsylvania, Philadelphia, PA USA
    • Department of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA USA
    • Corresponding Author InformationAddress reprint requests to Brian J. Czerniecki, MD, PhD, Department of Surgery, University of Pennsylvania, 4 Silverstein, 3400 Spruce St, Philadelphia, PA 19104.
    • ,
  • Isabelle Bedrosian

      Affiliations

    • Department of Surgery, University of Pennsylvania, Philadelphia, PA USA
    • Department of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA USA
    • ,
  • Mark Faries

      Affiliations

    • Department of Surgery, University of Pennsylvania, Philadelphia, PA USA
    • Department of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA USA
    • ,
  • Abass Alavi

      Affiliations

    • Department of Surgery, University of Pennsylvania, Philadelphia, PA USA
    • Department of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA USA

References 

  1. Cabanas R. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–466
  2. Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  3. Morton DL, Chan AD. The concept of sentinel node localizations: How it started. Semin Nucl Med. 2000;30:4–10
  4. Alex J, Weaver D, Fairbank J, et al. Gamma-probeguided lymph node localization in malignant melanoma. Surg Oncol. 1993;2:303–308
  5. Krag D, Meijer S, Weaver D, et al. Minimal access surgery for staging of malignant melanoma. Arch Surg. 1995;130:654–658
  6. Albertini J, Cruse C, Rapaport D, et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223:217–224
  7. Glass L, Messina J, Cruse W, et al. The use of intraoperative lymphoscintigraphy for sentinel node biopsy in patients with malignant melanoma. Dermatol Surg. 1996;22:715–720
  8. Gershenwald JE, Tseng C-h, Thompson W, et al. Improved sentinel lymph node localization in patients with primary melanoma with use of radiolabeled colloid. Surgery. 1998;124:203–210
  9. Alazraki NP, Eshima D, Eshima LA, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med. 1997;27:55–67
  10. Bergqvist L, Strand S-E, Persson BR. Particle sizing and biokinetics of interstitial lymphoscintigraphic agents. Semin Nucl Med. 1983;8:9–19
  11. Eshima D, Fauconier T, Eshima L, et al. Radiopharmaceuticals for lymphoscintigraphy: Including dosimetry and radiation considerations. Semin Nucl Med. 2000;30:25–32
  12. Faries MB, Bedrosian I, Reynolds C, et al. Active macromolecule uptake by lymph node antigen-presenting cells: A novel mechanism in determining sentinel lymph node status. Ann Surg Oncol. 2000;7:98–105
  13. Chang A, Aruga A, Cameron M, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol. 1997;15:796–807
  14. Valdes-Olmos R, Hoefnagel C, Nieweg O, et al. Lymphoscintigraphy in oncology: A rediscovered challenge. Eur J Nucl Med. 1999;26(suppl 4):S2–S10
  15. Burak W, Walker M, Yee L, et al. Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer. AmJ Surg. 1999;177:445–449
  16. McMasters K, Wong S, Tuttle T, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg. 2000;231:724–731
  17. Uren R, Howman-Giles R, Thompson J, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med. 1995;36:1775–1780
  18. Jansen L, Doting M, Rutgers E, et al. Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg. 2000;87:920–925
  19. Czerniecki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel node biopsy in patients with breast cancer. Cancer. 1999;85:1098–1103
  20. Johnson N, Soot L, Nelson J, et al. Sentinel node biopsy and internal mammary lymphatic mapping in breast cancer. Am J Surg. 2000;179:386–388
  21. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818–1822
  22. Turner RR, Ollila DW, Krasne DL, et al. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271–278
  23. O'Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998;186:423–427
  24. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 1997;349:1864–1867
  25. Borgstein P, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph node in breast cancer. Lancet. 1997;349:1668–1669
  26. Kern K. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg. 1999;189:539–545
  27. Joosten J, Strobbe L, Wauters C, et al. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. Br J Surg. 1999;86:482–486
  28. Bedrosian I, Faries M, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (<1mm) with vertical growth phase. Ann Surg Oncol. 2000;7:262–267
  29. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or stage II melanoma. J Clin Oncol. 1998;16:2253–2260
  30. Slingluff C, Stidham K, Ricci W, et al. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4,682 patients. Ann Surg. 1994;219:120–130
  31. Shen P, Guenther J, Wanek L, et al. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrence?. Ann Surg Oncol. 2000;7:114–119
  32. Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol. 1997;66:7–10
  33. Fisher B, Wolmark N, Redmond C, et al. Findings from NSABP Protocol No. B-04: Comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer. 1981;48:1863–1872
  34. Blaheta H, Ellwanger U, Schitteck B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular marker analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000;114:637–642
  35. Bostick P, Morton D, Turner R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 1999;17:3238–3244
  36. Reynolds C, Mick R, Donohue J, et al. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer?. J Clin Oncol. 1999;17:1720–1726
  37. Chu K, Turner R, Hansen N, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?. Ann Surg. 1999;229:536–541

PII: S0001-2998(01)80043-X

doi: 10.1053/snuc.2001.21270

Seminars in Nuclear Medicine
Volume 31, Issue 2 , Pages 158-164 , April 2001

Article Tools